# A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients

> **NCT01498081** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 39 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** AZD2115
- **DRUG:** Placebo
- **DRUG:** Indacaterol
- **DRUG:** Indacaterol + Tiotropium

## Key facts

- **NCT ID:** NCT01498081
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2012-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01498081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01498081, "A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01498081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*